William Oh, MD
-
- Position
- CLINICAL PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialties
- Cancer (Oncology)
- Hematology-Oncology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
-
Ruttenberg Treatment Center
1470 Madison Avenue
3rd Floor
New York, NY 10029
Phone: 212-241-6756212-241-6756
William K. Oh, MD, is Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers. Dr. Oh is also Chief Medical Science Officer at Sema4, a patient-centered health intelligence company and Mount Sinai Venture. Dr. Oh served as Chief of the Division of Hematology and Medical Oncology at Mount Sinai from 2009 to 2020 and as Deputy Director of The Tisch Cancer Institute at Mount Sinai from 2017 to 2020.
Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, he has developed large clinical databases and specimen repositories for genitourinary cancers at both Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancer.
Dr. Oh has authored more than 300 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade.
Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston.
Clinical Focus
- Adrenal Cortical Carcinoma
- Bladder Cancer
- Kidney Cancer
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
Education
MD, New York University School of Medicine
Residency, General Medicine
Brigham and Women's Hospital, Harvard Medical School
Fellowship, Medical Oncology
Dana Farber Cancer Institute
Language
English
2011
American Society of Clinical Investigation
2010-18
New York Magazine Best Doctors
2009-18
New York Super Doctors
2008-18
America’s Top Doctors for Cancer (Castle Connolly)
2007-8
Harvard Business School Physician Leadership Program
2003-18
Best Doctors in America
2003
Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention
1992
Alpha Omega Alpha
1992
Prize in Internal Medicine, NYU School of Medicine
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Oh during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Advanced Accelerator App
- Astellas Pharma Inc.
- AstraZeneca
- Bayer
- Curio Science
- Dendreon Corporation
- EXACT Sciences Corporation
- Foundry
- Merck & Co., Inc.
- Sema4
- TeneoBio
Service on Board of Directors: Service in a fiduciary capacity, such as an officer or director, for the following companies:
- Sema4
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.